FRANKLIN
LAKES, N.J., June 7, 2022
/PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a
leading global medical technology company, today announced it has
appointed Simon Campion as executive
vice president (EVP) and president of the Medical segment for BD,
effective July 1, 2022.
Campion, 51, will replace Alberto
Mas who previously announced his intent to retire from BD.
In this role, Campion will be responsible for the global strategic,
operational and commercial performance of the Medical segment
portfolio and will be accountable for delivering the segment's
innovation agenda aligned to the BD 2025 strategy. Campion will
also continue to lead the Interventional segment in the interim
until a successor is named. He will report to Tom Polen, chairman, CEO and president of
BD.
"Simon is a proven business leader with excellent strategic and
operational skills and deep global experience," said Polen. "Since
joining BD from the Bard acquisition, Simon has been integral in
the integration and growth of the legacy Bard businesses across the
Interventional segment and is well positioned to lead BD's largest
segment."
Campion has served as EVP and president of the Interventional
segment for BD since September 2018.
Prior to that he was president of the BD Surgery business unit,
where he integrated legacy Bard and BD product platforms into an
integrated Surgery offering. Campion joined Bard in 2008 and held
leadership roles in numerous Bard businesses in the U.S. and
Europe. Prior to Bard, he held
marketing and R&D roles at Cook Medical and Boston
Scientific.
Campion holds a Ph.D. in Mechanical Engineering from the
University of Limerick in Ireland
and a Master of Business Administration from The Open University in
the United Kingdom.
About BD
BD is one of the largest global medical
technology companies in the world and is advancing the world of
health by improving medical discovery, diagnostics and the delivery
of care. The company supports the heroes on the frontlines of
health care by developing innovative technology, services and
solutions that help advance both clinical therapy for patients and
clinical process for health care providers. BD and its 75,000
employees have a passion and commitment to help enhance the safety
and efficiency of clinicians' care delivery process, enable
laboratory scientists to accurately detect disease and advance
researchers' capabilities to develop the next generation of
diagnostics and therapeutics. BD has a presence in virtually every
country and partners with organizations around the world to address
some of the most challenging global health issues. By working in
close collaboration with customers, BD can help enhance outcomes,
lower costs, increase efficiencies, improve safety and expand
access to health care. For more information on BD, please visit
bd.com or connect with us on LinkedIn at
www.linkedin.com/company/bd1/ and Twitter @BDandCo.
Contacts:
|
|
|
|
Media:
|
Investors:
|
Troy
Kirkpatrick
|
Francesca
DeMartino
|
VP, Public
Relations
|
SVP, Head of Investor
Relations
|
858.617.2361
|
201.847.5743
|
troy.kirkpatrick@bd.com
|
francesca.demartino@bd.com
|
View original content to download
multimedia:https://www.prnewswire.com/news-releases/bd-names-simon-campion-as-medical-segment-president-301562231.html
SOURCE BD (Becton, Dickinson and Company)